.png)
metamorworks/iStock via Getty Images
atai Life Sciences (ATAI) reported promising data on Tuesday from the second part of a mid-stage trial of BPL-003, a psychedelic therapy being developed by Beckley Psytech, for treatment-resistant depression.
Beckley Psytech and atai Life Sciences signed an agreement in
English (US) ·